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Abstract
Background: Therapeutic inertia (TI) is a common phenomenon among physicians who care for patients with chronic
conditions. We evaluated the efficacy of the traffic light system (TLS) educational intervention to reduce TI among
neurologists with MS expertise. Methods: In this randomised, controlled trial, 90 neurologists who provide care to
MS patients were randomly assigned to the TLS intervention (n = 45) or to the control group (n = 45). The educa-
tional intervention employed the TLS, a behavioral strategy that facilitates therapeutic choices by facilitating reflec-
tive decisions. The TLS consisted in a short, structured, single session intervention of 5-7 min duration. Participants
made therapeutic choices of 10 simulated case-scenarios. The primary outcome was a reduction in TI based on a
published TI score (case-scenarios in which a participant showed TI divided by the total number of scenarios where
TI was possible ranging from 0 to 8). Results: All participants completed the study and were included in the primary
analysis. TI was lower in the TLS group (1.47, 95% CI 1.32-1.61) compared to controls (1.93; 95% CI 1.79-2.08).
The TLS group had a lower prevalence of TI compared to controls (0.67, 95% CI 0.62-0.71 vs. 0.82, 95% CI 0.78-
0.86; p = 0.001). The multivariate analysis, adjusted for age, specialty, years of practice, and risk preference showed
a 70% reduction in TI for the TLS intervention compared to controls (OR 0.30; 95% CI 0.10-0.89). Conclusions: In
this randomized trial, the TLS strategy decreases the incidence of TI in MS care irrespective of age, expertise, years
for training, and risk preference of participants, which would lead to better patient outcomes.
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The management of multiple sclerosis (MS) evolves with
the availability of new disease-modifying agents, varying
dosage forms (oral, injectable, infusion), and different
safety and efficacy profiles. As a result, physicians who care
for MS patients face more complex therapeutic decisions
when considering individual patients, number of relapses,
activity on brain imaging, and the need to escalate therapy.
Moreover, many MS patients remain undertreated.1–3
Therapeutic inertia (TI) corresponds to the absence of
treatment initiation or intensification when treatment
goals are unmet. It affects more than 50% of clinicians
caring for patients with chronic conditions.1,4–6 Insufficient
knowledge integration and knowledge-to-action gaps are
among the most common explanations for suboptimal
therapeutic decisions. However, TI is a complex process
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also related to other characteristics of the providers such
as lack of knowledge about appropriate goals, high patient
volume, and time constraints. Some physicians fail to inte-
grate the available information (e.g., severity of the condi-
tion, risk of progression, imaging findings affecting
outcomes) with best practice recommendations for a given
risk-scenario.7–10 Furthermore, physicians have limited
training in risk management and formal learning in medi-
cal decision making.11–13 All of these factors may contrib-
ute to TI and undertreatment.
Educational interventions have been designed to
optimize knowledge integration and bridge knowledge-
to-action gaps for complex medical decisions (e.g., diag-
nostic challenges, varying risk categories, availability of
multiple agents with a broad range of safety/efficacy
ratio).11 One such intervention is the traffic lights system
(TLS). The TLS emerged as risk categorization and
warning strategy to reduce human errors that relies on
a relatively automatic, well-established, and cross-
cultural concept to increase the chance of an optimal
course of action.14,15 The TLS facilitates the decision-
making process using traffic light terminology, which
creates a link between a color, representing a risk level,
and an action: red light (‘‘high risk’’/‘‘stop and think’’),
yellow light (‘‘intermediate risk’’/‘‘reassess soon’’), and
green light (‘‘low risk’’/‘‘continue the same strategy’’).
For example, studies showed that the TLS facilitates
healthier food choices by interrupting automatic behavior
and triggering a reevaluation processes.16 A functional
magnetic resonance imaging study showed that TLS
labels enhance the coupling between brain regions associ-
ated with valuation (i.e., ventromedial prefrontal cortex)
and self-control.17 Evidence from the literature suggests
that medical decisions leading to TI are likely related to
knowledge-to-action gaps.7 The design and application of
the TLS as an educational intervention provides a unique
opportunity to overcome knowledge-to-action gaps in
MS care.18
In a previous pilot study, we assessed the feasibility
and potential efficacy of a TLS educational intervention
in 25 neurologists from Spain.19 TI was present in
72.0% of participants in at least one case scenario. The
primary feasibility outcome, the completion rate of the
study, was 100% (25/25 participants). While not pow-
ered to detect a significant difference between groups,
our pilot study demonstrated a nonsignificant reduc-
tion in TI for the targeted intervention group relative
to the control group (22.6% v. 33.9% postintervention;
odds ratio [OR] = 0.57; 95% confidence interval [CI]
= 0.26 to 1.22).19 The TLS also showed a high usabil-
ity score (74.7; 95% CI = 70.1 to 79.2) when tested in
a larger study comprising neurologists from Argentina,
Chile, and Canada.20
In the present study, we evaluated the efficacy of our
simple and pilot-tested educational TLS intervention for
reducing TI among neurologists who routinely provide
care of MS patients.
Methods
Study Design and Participants
The overarching goal of the TLS intervention was to
facilitate the integration of gaps between risk stratifica-
tion and treatment decisions (initiation or escalation) in
MS care. Specifically, our randomized parallel trial tested
the efficacy of an educational TLS intervention (active
group) against usual care (control group) for reducing TI
in the management of MS (Figure 1). Participants were
randomly assigned (1:1 ratio) to the TLS or the control
group by Qualtrics (Qualtrics.com; Online Appendix,
Figure e1). Allocation concealment was implemented in
Qualtrics, so that participants did not know which inter-
vention they were allocated to after completing the initial
demographic information. Investigators were also
blinded to the treatment allocation. Participants were
recruited by automatic e-mail invitation from the study
platform. The Institute of Neuroscience Buenos Aires
and the Argentinian Neurological Society facilitated the
mailing of information to potential participants who met
the inclusion criteria.
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Data Collection
Participants answered questions as follows: 1) demo-
graphic and practice-based information, 2) behavioral
experiments, and 3) 10 case scenarios that assessed TI.
Behavioral experiments used previously established
designs to assess participants’ risk preferences and toler-
ance to ambiguity in the health and financial
domains.21,22 In brief, ambiguity aversion is defined as
dislike for events with unknown probability compared to
events with known probability.21 For example, in the
medical domain, an ambiguity-averse individual would
rather choose a treatment where the probability of bene-
fits or side effects is known (even if these are somewhat
unfavorable) over one where this probability is unknown
(Figure 2A and B). Risk experiments involved determin-
ing the subjective value of a risky (50/50) option in terms
of a safe (100%) option. By asking participants to indi-
cate the magnitude of the safe option at which they
would be indifferent between the two options, we were in
a position to determine the point of subjective equiva-
lence of the risky and the safe option. The higher this
point, the higher the propensity to take risk. Further
details of these experiments were published in previous
studies (and appendix).3
Participants were also asked to select those MS drugs
that they use and then rank them from a list including all
available agents approved by the local regulatory body in
Figure 1 Consort flow diagram. Of 117 eligible participants, 90 participants were randomized to the educational intervention (n=
45) and control (n= 45). All participants completed the intervention and contributed a complete set of data to the analysis.
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Figure 2 Experiments to assess ambiguity in the financial and health domains. Participants were told to imagine two different
types or urns. For urn type A, they knew that 50% of the balls were red and the other 50% were blue. For urn type B, they did
not know the exact proportion of blue to red balls, with the grey bar representing the unknown proportion of balls. For the
financial domain (Panel A), participants knew that if they drew a blue ball, they would win the full amount of $400. If they drew
a red ball, they would win $ 0. For the health domain (Panel B), participants decided between two treatments for a patient. With
‘‘Treatment A,’’ the patient had a 50% probability of survival. With ‘‘Treatment B,’’ the exact probability of survival was
unknown, with the grey bar representing the unknown probability. In our tasks, participants were asked to choose between one
option (presented as two-colored bar) with known 50/50 probability of winning 400 or 0 American dollars (urn A) versus an
option with unknown probability of the same outcomes (urn B). Participants who chose the 50/50 options were classified as
averse to ambiguity; the remaining participants were classified as tolerant to ambiguity.1 A similar approach was used to
determine aversion to ambiguity in the health domain (Panel B).
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Argentina by March 30, 2018. The purpose of this strat-
egy was to compare how TI derived from case scenarios
relates with agents used for treatment escalation (e.g., fin-
golimod, natalizumab, alemtuzumab) in routine clinical
practice. At the time of conducting this trial, cladribine
and ocrelizumab were not available and therefore not
included in case scenarios.
In line with the learning and education literature,
vignettes, clinical case scenarios, or ‘‘real-world’’ encoun-
ters are regarded as the best simple strategy to evaluate
potential cognitive biases and medical decisions.23 Case
scenarios were designed by our research team and MS
experts derived from the most common situations in clin-
ical practice as previously reported in our pilot study.19
Eight case scenarios were designed to assess appropriate
treatment initiation or escalation, whereas the remaining
two cases were designed to assess overtreatment (defined
as treatment escalation when there was low risk of dis-
ease progression and no evidence of disease activity).24–26
Participants from each randomized group were exposed
to the same case scenarios. Inclusion criteria comprised
neurologists who were actively involved in managing MS
patients. Physicians whose practice was primarily in car-
ing for MS patients or who obtained a subspecialty
degree were classified as ‘‘MS specialists.’’ Physicians
who were not practicing neurology or seeing less than
one MS patient per month were excluded from the study.
Definitions
For the primary analysis, bad prognosis was defined as
the combination of a clinical relapse plus the presence of
new brain lesions in follow-up magnetic resonance ima-
ging (MRI) scans or at least one gadolinium-enhancing
lesion.27,28 All high-risk cases included a description of
an MRI with more than five new T2 lesions or at least
one enhancing lesion.29 The use of these definitions com-
bining a clinical relapse and MRI activity is consistent
with recent evidence regarding the risk of treatment fail-
ure among patients receiving interferon-b.30 Disease pro-
gression was defined as at least one point worsening
from baseline to 1-year follow-up in the Expanded
Disability Status Scale (EDSS) score.31 Recent meta-
analysis confirmed that alemtuzumab, natalizumab, and
fingolimod are the best available choices for preventing
clinical relapses in patients with relapsing-remitting MS
(RRMS).32 The current treatment option for RRMS
include first-line (b-interferons, glatiramer acetate),
second-line (fingolimod, cladribine), and third-line (nata-
lizumab, alemtuzumab, ocrelizumab) therapies. For the
present analysis, we used the aforementioned scheme
according to the current clinical practice.24–26,33
The Traffic Light System (Figure 3)
In our study, the TLS was applied to help participants
identify scenarios with poor prognosis (high risk of dis-
ease progression; Figure 3B). Consequently, participants
would be able to identify the ‘‘red’’ traffic light as a
warning sign for a high-risk situation, and subsequently
escalate treatment. The ‘‘yellow’’ traffic light represents
caution for scenarios with either a clinical relapse or
some degree of activity on brain imaging (but not both),
which requires a reassessment within 6 to 12 months.
The control group made therapeutic decisions without
being exposed to the TLS intervention as part of the cur-
rent standard practice. Further details of the TLS inter-
vention are described elsewhere.19 An example of the
presented case scenario is represented in Figure 3C.
Outcome Measures
Therapeutic inertia was the primary outcome of interest,
measured as a continuous variable (TI score) and as bin-
ary. The TI score was defined as the number of case sce-
narios in which a participant showed TI (ranging from 0
to 8). The TI score was reported in our previous studies
to reflect the magnitude of TI.19,34 A low TI score repre-
sents low TI, whereas a higher score represents higher. A
0.5 point difference in the TI score was deemed as clini-
cally meaningful given the impact in clinical practice. In
our study, detecting a difference equal to or greater than
0.50 between groups in the TI score would represent a
clinically meaningful improvement. The TI score was
derived from case scenarios, which were aligned with the
current Argentinian, North American, and European
practice recommendations.24–26
A reduction in the TI score reflects that participants
appropriately switched from a first-line agent (e.g., gla-
tiramer, interferons) to a high-efficacy treatment (e.g.,
fingolimod as a second-line therapy or monoclonal anti-
bodies as third-line therapies) when clinical and radiolo-
gical evidence of disease progression.
TI as a binary outcome was defined as the proportion
of participants demonstrating TI in at least one of the
eight scenarios (prevalence of TI).
Statistical Analysis
We used parametric tests (t test and Fisher’s exact test) to
compare continuous and categorical variables between
Saposnik et al. 5
Figure 3 The TLS intervention. Panel A illustrates background information on the TLS and application to therapeutic decisions.
Panel B illustrates how the TLS facilitates the decision-making process using traffic light terminology, which creates a link
between a color, representing a risk level, and an action: red light (‘‘high risk’’/‘‘stop and think’’), yellow light (‘‘intermediate
risk’’/‘‘reassess soon’’), and green light (‘‘low risk’’/‘‘continue the same strategy’’). Panel C provides a case scenario as an example
of those given the participants.
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groups. Linear regression analysis was used to determine
the efficacy of the TLS for reducing TI scores in the inter-
vention group versus the control group. Similarly, logistic
regression analysis was used to determine the efficacy of
the TLS with respect to the proportion of participants
with TI in at least one case scenario. We also evaluated
the association between restrictions for prescribing DMTs
and the number of second- and third-line agents com-
monly used in clinical practice with the TI score.
For multivariate analysis of individual responses, we
constructed multilevel mixed-effects models where parti-
cipants (n = 90) and individual responses (n = 720; 90
participants each completing 8 case scenarios) entered as
random effects. The aim of this analysis was to evaluate
the contribution of individual-specific variables to the
variation of TI. Given the findings from our previous
studies, we included the following a priori variables: par-
ticipant age, expertise (MS specialist v. general neurolo-
gist), years of experience, and aversion to ambiguity.3,19
All tests were 2-tailed, and P values \0.05 were consid-
ered significant. We used STATA 13 (StataCorp LP,
College Station, TX) to conduct all analyses.
Further details of the protocol are published in
ClinicalTrials.gov (# NCT03134794).
Results
Out of the 117 neurologists with expertise in MS care
who were invited to participate in the study, 90
completed the survey (response rate 76.9%) between
April and September 2018. There was representation
from all provincial territories. The mean (SD) age was
46.4 (610.3) years; 48 (53%) were male neurologists.
Thirty-one (34.4%) participants primarily focused their
practice on MS care. They had 20.3 (610.9) years of
practice and were assessing 22 (66.6) MS patients per
week. Table 1 compares baseline characteristics between
groups. Groups did not differ in demographics or in risk
preferences as measured by the behavioral risk tasks (P
= 0.40 for risk preferences and P = 0.63 for aversion to
ambiguity). There were no differences in treatment esca-
lation at baseline between groups. On average, partici-
pants in the TLS group used 3.09 agents for treatment
escalation versus 2.91 in the control group (P = 0.62).
There was no association between participants’ restric-
tions to prescribe MS drugs and TI score (P = 0.44) or
the prevalence of TI (P= 0.78).
Table 2 summarizes the primary and secondary out-
come measures at the participant and individual response
levels. TI scores were significantly lower in the TLS inter-
vention group than in the control group (1.36, 95%
CI = 1.23 to 1.50, v. 2.04, 95% CI = 1.90 to 2.17) after
adjustment for the prespecified variables (age, specialty,
years of practice, and risk preferences). The observed
0.68 difference between groups in the adjusted TI scores
was greater than the minimal clinically meaningful mea-
sure of 0.5 to detect an improvement. Similarly, partici-
pants in the TLS intervention group had a lower
Table 1 Baseline Characteristics of Participants
Characteristics Control (N= 45) Educational Intervention (N= 45) P Value
Age in years (mean 6 SD) 46.8 6 10.3 46.0 6 10.4 0.72
Sex, n (%) 0.67
Female 20 (44.4) 22 (48.9)
Male 25 (55.6) 23 (51.0)
Specialty, n (%) 0.82
General neurologists who care for MS patients 29 (64.4) 30 (66.7)
MS specialists 16 (35.6) 15 (33.3)
Practice setting, n (%) 0.37
Public 17 (37.8) 13 (28.9)
Private 28 (62.2) 32 (71.1)
% time in clinical practice, n (%)
.75% 19 (42.2) 20 (44.4) 0.83
Years in practice (mean 6 SD) 21.1 6 10.5 19.5 6 11 0.48
MS patients seen per week (mean 6 SD) 21.8 6 4.5 23.0 6 8.3 0.37
Author of a peer-reviewed publication in the last 1 year, n (%) 20 (44.4) 23 (51.1) 0.53
Restriction to prescribe MS drugs, n (%) 0.83
No restrictions 28 (62.2) 29 (64.4)
Treatment escalation, mean drugs (6SD) 2.91 (1.24) 3.09 (2.05) 0.62
MS, multiple sclerosis
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prevalence of TI compared to controls (63.7%, 95%
CI = 58.9% to 68.6%, v. 83.9%, 95% CI = 80.4% to
88.4%) (Figure 4).
The multivariate analysis also revealed a significant
reduction in the TI score for the TLS intervention com-
pared to the control group (b = 20.68; 95% CI =
21.24 to 20.11). The multivariate logistic regression
analysis showed 70% reduction in the odds of TI for the
TLS group (OR = 0.30, 95% CI = 0.10 to 0.89).
Specialist status (P = 0.002), higher years of experience
(P = 0.007), and tolerance to ambiguity (P = 0.043)
were associated with lower TI. The adjusted models
showed good discrimination (c-statistic = 0.74) and cali-
bration (goodness-of-fit test P= 0.52).
Results were consistent for the analyses of individual
responses (Table 2). There were no significant differences
between fixed and random effect models (data not
shown). Figure 3 represents the relationship between the
observed and predicted TI scores (Figure 5A) and strati-
fies the data by group (Figure 5B), revealing that TI was
consistently lower in the intervention group.
Participants who commonly used agents for treatment
escalation in their daily practice had lower TI scores
(1.48 v. 1.8; P \ 0.01). Accordingly, participants who
do not commonly use agents for treatment escalation in
their daily practice benefited from the intervention (for
TI score: b = 20.78, 95% CI = 21.03 to 20.52; for TI
prevalence: OR = 0.56, 95% CI = 0.36-0.88).
The analysis of individual responses also revealed that
for every 100 MS patients with a bad prognosis (e.g.,
both clinical and radiological evidence of disease
activity), there will be over 24 patients who will remain
with the same treatment if managed by neurologists
without educational intervention (control group). That
number would be decreased to 10 patients if treated by
neurologists who received the TLS educational
intervention.
Discussion
In the present randomized controlled trial (RCT), we
evaluated the efficacy of a newly designed pilot-tested19
educational intervention to overcome TI among practi-
cing neurologist care for MS patients. We found TI in 7
out of 10 participating neurologists in at least one case
scenario. The TLS educational intervention was associ-
ated with a 68% reduction in the TI score or 70% reduc-
tion in the odds of TI. In other words, participants
appropriately choose a higher efficacy treatment (e.g.,
monoclonal antibodies) instead of continuing with the
same agents (e.g., glatiramer, interferon) when clinical
and radiological evidence of disease progression. The
effect of the educational intervention was similar for all
categories of TI scores. Specialist status, years of experi-
ence, and tolerance to ambiguity were associated with
lower TI. Moreover, selection of common agents used
for treatment escalation in participants’ routine practice
was associated with lower TI scores. More interestingly,
the TLS intervention was effective among participants
who do not commonly use agents for treatment escala-
tion in their daily practice by showing a significant
reduction in TI. Our results were consistent for the
Table 2 Multivariate Analysis for the Primary and Secondary Outcome Measuresa
Outcome Measures Control Intervention
Difference Between
Groups
Multivariate Regression
Analysis (95% CI)
Primary outcome
Participant-level analysis n = 45 n = 45
TI score, mean (SD) 1.93 (1.42) 1.47 (1.42) (0.46) 20.68 (21.24 to 20.11)b
Secondary outcome measures
TI (present v. absent) in at least one
case scenario, n (%)
37 (82.2) 30 (66.7) (15.5) 0.30 (0.10 to 0.89)c
Individual responses n = 360 n = 360
TI score, mean (SD) 1.93 (1.41) 1.47 (1.41) (0.46) 20.68 (20.87 to 20.48)d
TI present versus absent, n of
individual responses/total
87/360 (24.2) 66/360 (18.3) (5.9) 0.60 (0.41, 0.88)d
CI, confidence interval; OR, odds ratio; TI, therapeutic inertia.
aAll models adjusted for age, specialty, years of practice, risk preference, and group (intervention v. control).
bDerived from linear regression models and expressed in b coefficients (95% CI) with TI score as dependent variable.
cDerived from multivariate logistic regression analysis with TI (present v. absent) as dependent variable.
dDerived from multilevel mixed effects models expressed as OR (95% CI) for binary outcomes (TI present v. absent) and b coefficients (95% CI)
for the TI score.
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analysis at the participant level and individual responses
for both categories of TI and TI scores.
There are not many proven effective interventions in
medical education associated with improvements in clini-
cally meaningful outcomes.35 A recent systematic review
evaluated 302 controlled studies that had investigated the
effect of evidence-based educational interventions. Of 85
articles that met the inclusion criteria, 46 (54%) studies were
randomized trials, 51 (60%) included postgraduate-level
participants. Although the authors evaluated outcomes in
multiple domains (e.g., self-efficacy, knowledge, behavior
change), none of the studies assessed patients’ benefits.35 In
MS care, TI may lead to undertreatment. By extension, the
TLS intervention used here may eventually have patient
benefits if it reduces TI in MS care.
We used TLS to reduce TI in MS care. Previous
authors proposed the TLS to monitor treatment response
in patients with RRMS. They included a more
Figure 4 TLS intervention decreased therapeutic inertia (TI). (A) Comparison of adjusted TI scores in the intervention and
control groups. This graph was derived from the multivariate linear regression analysis adjusted for age, years of practice,
participants risk preference, and specialty (general neurologist v. MS expert). TI scores were significantly higher in the control
group compared to the intervention group (*P value\0.001). (B) Comparison of adjusted prevalence of TI between the
intervention and control groups. This graph was derived from the multivariate logistic regression analysis adjusted for age, years
of practice, participants risk preference, and specialty (general neurologist v. MS expert). The prevalence of TI was significantly
higher in the control group compared with the intervention group (*P value\0.001).
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sophisticated scoring system (0 to 3) for different cate-
gories (clinical relapses, evidence of disease progression,
cognitive status, and MRI findings) making practical use
in daily practice more difficult. This scoring system leads
to a decision model that uses the TLS to facilitate thera-
peutic choices.36 However, this strategy has not been pre-
viously tested in a RCT. The findings of our RCT
suggest that the TLS may be a useful medical educational
intervention, in keeping with research on the manage-
ment of obesity, fever in children, blood pressure control,
and healthy food choices.14,15
Our results have limitations that deserve comment.
First, our sample size is relatively small. However, our
RCT was designed and powered to detect differences in
TI following our pilot study.19 Second, case scenarios
may not necessarily reflect participants’ daily practice.
It is also possible that general neurologists apply the
‘‘first do not harm rule’’ when not escalating treatment
(commonly associated with more severe side effects).
Following these arguments, our study underestimates the
prevalence of TI in real-life practice given a tightly con-
trolled environment and applicability of treatment
Figure 5 Adjusted probability of therapeutic inertia (TI). (A) Adjusted probability of TI as a function of TI scores. (B) Adjusted
TI score categories stratified by intervention assignment group. The x-axis represents categories of the TI to evaluate whether the
intervention had a different effect among participants with low, medium, and high TI scores. The y-axis represents the TI scores
to be able to show the lack of overlap of 95% CI between TLS and controls for each TI category (P value TLS v. controls =
0.02). Data derived from multivariate linear regression with TI score as the dependent variable. ‘‘I’’ represent 95% CI error bars.
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recommendations in our RCT design. Third, we cannot
rule out the possibility that unmeasured confounders
(e.g., health policy, restrictive prescription rules) may
play a role for the studied outcome measures. We con-
trolled for this issue by measuring the prevalence of pre-
scription restrictions in the workplace for each
participant. No association was found between prescrip-
tion restrictions and the outcomes of interest. Fourth, we
have no information regarding the sustainability of the
TLS effect on TI given the design of our study. Future
research will be needed to investigate this question.
Finally, the definition of TI applied to MS care may not
be widely used. Nevertheless, we used a practical and
conservative definition of TI (absence of escalation with
the concomitant presence of a clinical relapse and evi-
dence of imaging activity) consistent with our previous
studies, which is supported by guidelines showing
improvements in clinical outcomes when escalating
therapies (i.e., blood pressure and diabetes).6,24,26
In the evolving landscape of MS treatment, new and
more effective agents with improvements in safety pro-
files are becoming available.33 Despite such advance-
ments, many MS patients remained undertreated.25,26
Several conditions affect the risk of TI, but physicians’
factors are regarded as the most influential.33 Our results
revealed that an innovative and highly usable educa-
tional intervention may revert the incident risk of TI
among neurologists who care for MS patients. This is
also supported by the following facts: 1) participants
who commonly use agents for treatment escalation had
lower TI, 2) the significant reduction in TI for the TLS
intervention group among neurologist who do not com-
monly use agents for treatment escalation, and 3) the
relevance of the role of MS specialist in making thera-
peutic decisions given the lower prevalence of TI.
Our findings have practical clinical and health policy
implications, which may not only lead to improving out-
comes for patients but also to the implementation of
educational interventions in physicians managing high-
risk and complex patients. Our intervention has the
potential to be translated to other highly prevalent medi-
cal conditions, including the management of hyperten-
sion, diabetes, and dyslipidemia commonly affecting
individuals at high risk of cardiovascular and cerebro-
vascular diseases.
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